Cargando…

Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?

(1) Background: The current study aimed to compare two of the most frequently prescribed preservative-free (PF) antiglaucoma drops, (Latanoprost PF vs. Bimatoprost PF) in promoting OSD in patients with POAG. (2) Methods: In this prospective study, 44 eyes from 44 participants were included. In the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimtsas, Georgios S., Tsiogka, Anastasia, Moschos, Marilita M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648670/ https://www.ncbi.nlm.nih.gov/pubmed/37959198 http://dx.doi.org/10.3390/jcm12216732

Ejemplares similares

Tear biomarkers in latanoprost and bimatoprost treated eyes
por: Reddy, Shweta, et al.
Publicado: (2018)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways
por: Li, Xiaohong, et al.
Publicado: (2016)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

The Demographic and Social Characteristics of Patients with Ocular Foreign Bodies in a Greek Tertiary Hospital
por: Kousiouris, Panagiotis, et al.
Publicado: (2022)

Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients
por: Cordeiro, M Francesca, et al.
Publicado: (2015)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
por: Chen, Wensheng, et al.
Publicado: (2014)

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

The Book of PF
por: Hansteen, Peter
Publicado: (2014)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
Publicado: (2014)

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases
por: Yamada, Hiroshi, et al.
Publicado: (2016)

Advances in Diagnosis and Treatment of HPV Ocular Surface Infections
por: D. Kalogeropoulos, Chris, et al.
Publicado: (2015)

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]
por: Zeitz, Oliver, et al.
Publicado: (2005)

Misclassification of PfEH1 and PfEH2 as Epoxide Hydrolases
por: Arand, Michael, et al.
Publicado: (2017)

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial
por: Rossetti, Luca, et al.
Publicado: (2015)

16 pf-5
por: Russell, M. T.
Publicado: (2003)

Reply to “Misclassification of PfEH1 and PfEH2 as Epoxide Hydrolases”
por: Goldberg, Daniel E., et al.
Publicado: (2017)

Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice
por: Longley, Rhea J., et al.
Publicado: (2015)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Test Results from the PF Conductor Insert Coil and Implications for the ITER PF System
por: Bessette, D, et al.
Publicado: (2009)

pfSense 2 Cookbook
por: Williamson, Matt
Publicado: (2011)

pfSense 2.x cookbook: manage and maintain your network using pfSense
por: Zientara, David
Publicado: (2018)

PfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockers
por: Eastman, Richard T., et al.
Publicado: (2016)

Structure of the Pf12 and Pf41 heterodimeric complex of Plasmodium falciparum 6-cysteine proteins
por: Dietrich, Melanie H, et al.
Publicado: (2022)

Localization of the ATP-binding cassette (ABC) transport proteins PfMRP1, PfMRP2, and PfMDR5 at the Plasmodium falciparum plasma membrane
por: Kavishe, Reginald A, et al.
Publicado: (2009)

Performance of Paracheck™-Pf, SD Bioline malaria Ag-Pf and SD Bioline malaria Ag-Pf/pan for diagnosis of falciparum malaria in the Central African Republic
por: Djallé, Djibrine, et al.
Publicado: (2014)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Comparative performance of four malaria rapid diagnostic tests, Vikia Malaria Pf/Pan, Meriline-Meriscreen Pf/Pv/Pan, Right Sign Malaria Pf/Pan, and Right Sign Malaria Pf, among febrile patients in Gabon
por: Ditombi, Bridy Chesly Moutombi, et al.
Publicado: (2020)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: Craven, E Randy, et al.
Publicado: (2010)

16 PF-5 : cuestionario factorial de personalidad /
por: Russell, Mary T.
Publicado: (2013)

Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum
por: Sharma, Aabha I., et al.
Publicado: (2020)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Moving from PF-ILD to PPF
por: Bhattacharyya, Parthasarathi
Publicado: (2023)

Positron beams for the PF storage ring
por: Ohsawa, S, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_phg0ojlb4reoph00f63hskirhh